[Alpha-chain disease].
The pathological and clinical features of alpha-chain disease, its immunological diagnosis, the structural abnormalities of the abnormal immunoglobulin A compared with those of proteins of gamma and mu heavy chains diseases, the course of the disease and its present treatment, the epidemiological factors involved and their influence on pathogenesis and finally, the relationship with the "Mediterranean abdominal lymphoma" or IPSID are successively described. The stress has been placed on the latest data which refine but no not modify the first description of the disease. In the same way as studies on the synthesis and structure of proteins in heavy chain diseases will provide new data on the biosynthesis of normal immunoglobulins, so the elucidation of sequential events leading from a plasmocytic stage reversible by antibiotic therapy alone to a highly malignant immunoblastic stage should improve our knowledge of the genesis of human lymphomas.
Rambaud
J C
JC
Jian
R
R
Galian
A
A
Seligmann
M
M
D004066:Digestive System Diseases / Q000276:immunology; D006362:Heavy Chain Disease / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D006801:Humans; D007137:Immunoglobulin alpha-Chains / Q000032:analysis / Q000235:genetics; D008223:Lymphoma / Q000175:diagnosis; D012140:Respiratory Tract Diseases / Q000276:immunology; D013997:Time Factors
D007137:Immunoglobulin alpha-Chains
Maladie des chaînes alpha.